MCM
BCAX

MAI Capital Management’s Bicara Therapeutics BCAX Stock Holding History

MAI Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-57
Closed -$1.13K – 4900
2026
Q1 		$1.13K Buy
57
+12
+27% +$207 ﹤0.01% 4133
2025
Q4 		$758 Buy
+45
New +$769 ﹤0.01% 3713

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MAI Capital Management's BCAX Position: Q2 2026 in Review

MAI Capital Management sold out of Bicara Therapeutics (BCAX) in Q2 2026, closing a stake of 57 shares — an estimated $1.13K sold.

MAI Capital Management first reported a position in BCAX in Q4 2025 and held it in 2 quarters. The position peaked at $1.13K in Q1 2026. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • MAI Capital Management reported no remaining Bicara Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 57 Bicara Therapeutics shares in Q2 2026, an estimated $1.13K.
  • MAI Capital Management first reported a position in Bicara Therapeutics in Q4 2025 and held it in 2 quarters.
  • MAI Capital Management's Bicara Therapeutics position peaked at $1.13K in Q1 2026.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.